News | April 06, 2015

SCAI 2015 Opening Session to Highlight Disruptive Technologies in Cardiovascular Care

Drs. Peter Fitzgerald and Christian Assad-Kottner will examine impacts of rising costs, variability in care and encourage physicians to embrace change

April 6, 2015 — The opening session speakers at the Society for Cardiovascular Angiography and Interventions (SCAI) 2015 Scientific Sessions will examine the current state of cardiovascular care and why it is ripe for disruption and new technologies. Peter Fitzgerald, M.D., Ph.D., of Stanford University, and Christian Assad-Kottner, M.D., of the Fogarty Institute for Innovation and El Camino Hospital in Mountain View, California, will explore how increasing costs and variability in healthcare provide the potential to change how cardiovascular care is provided. SCAI 2015 will be held in San Diego May 6-9.

“Variability in care, health system consolidation and increasing financial pressures are driving an increasing need for standardization,” said Fitzgerald. “At the same time, innovative companies like Apple, Google and Samsung are entering healthcare. This convergence will drive greater change in how interventional cardiologists provide care, and it’s something we can all embrace.”

In his presentation, Fitzgerald will share examples of how emerging technologies will lead to better care. “Incredible point-of-care diagnostics are available today,” he said. “Soon we’ll be able to model the size and length of stent needed before we get to the cath lab. And we’ll be able to better assess the patient’s outcomes – that’s exciting because we can provide even better care, more efficiently and possibly for more patients.”

Interventional cardiologists will also need to understand and use new exponential technologies, which are types of technologies that rapidly evolve even as they fundamentally change medicine, according to Assad-Kottner. Examples include 3-D printing, robotics, genomics, sensors and artificial intelligence. Physicians are just beginning to understand and evaluate how these and other technologies can impact patient care.

“We have the ability to take our medical knowledge and use new technologies to creatively solve the problems we face today,” said Assad-Kottner.

Already, young physicians are beginning not only to embrace these changes but also to demand them, said Fitzgerald. As medical schools broaden their focus to include business, healthcare economics and information technology, young physicians are entering the field better prepared for the changes that are ahead.

“The students are demanding the change,” said Fitzgerald. “Our 30-year-olds are emerging from medical schools with so much more in their armamentarium. Still, there’s a lot of wisdom experienced interventional cardiologists can share to improve these new systems. We all need to get involved because it’s an exciting time for the field of interventional cardiology.”

For more information:

Related Content

Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab | November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab | November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Overlay Init